Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nations leading provider of diagnostic information services, today announced the launch of MelaNodal...
Source: prnewswire.com